Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1Phase 1 1

Status

Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other 1Gynecologic 1Gastrointestinal 1

Conditions

Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Overweight 1Obesity 1Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 642pembrolizumab 565Magnetic Resonance Spectroscopy 548Carboplatin 426Cisplatin 377Cyclophosphamide 374Biopsy 365Paclitaxel 306Nivolumab 303Gemcitabine 303Radiotherapy 274Bevacizumab 240Dexamethasone 209fludarabine 207Docetaxel 191durvalumab 183atezolizumab 177Oxaliplatin 174venetoclax 168Fluorouracil 167Rituximab 166Pemetrexed 164Capecitabine 161Radiation 159Doxorubicin 159Radiosurgery 150Etoposide 137Ipilimumab 135Leucovorin 133Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
semaglutide × 90 days × Clear all
NCT07627191 2026-06-05

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

University of Arizona

Phase EARLY_PHASE1 Not yet recruiting
30 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

NCT06222437 2026-03-23

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Methodist Health System

Phase 1 Withdrawn

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡